Literature DB >> 8250454

Incidence of cancer among men with the Felty syndrome.

G Gridley1, J H Klippel, R N Hoover, J F Fraumeni.   

Abstract

OBJECTIVE: To estimate the incidence of cancer (especially lymphoproliferative malignancies) in patients with the Felty syndrome.
DESIGN: A retrospective cohort study.
SETTING: A computerized database of all discharge records for 1969 to 1990 from a Veterans Affairs hospital. PATIENTS: 906 men with a discharge diagnosis of the Felty syndrome. MEASUREMENTS: Standardized incidence ratios (SIR) (ratios of observed-to-expected events) estimated the risk for specific cancers. Hospital records confirmed the diagnoses of the Felty syndrome and cancer.
RESULTS: We observed a twofold increase in total cancer incidence (137 patients; SIR = 2.09; 95% CI, 1.8 to 2.5). The risk for non-Hodgkin lymphoma (19 patients; SIR = 12.8, CI, 7.7 to 20.0) was much greater than the twofold increase in risk for lymphoma generally reported for rheumatoid arthritis. The risk for leukemia was increased but only within 5 years of the first hospitalization for the Felty syndrome, (13 patients; SIR = 7.67; CI, 4.1 to 13.1).
CONCLUSION: The increased risk for non-Hodgkin lymphoma after the Felty syndrome in our study is similar to the risk associated with the Sjögren syndrome and may reflect similar immunostimulatory mechanisms.

Entities:  

Mesh:

Year:  1994        PMID: 8250454     DOI: 10.7326/0003-4819-120-1-199401010-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

Authors:  Anna K Wong; Susan Kerkoutian; Jonathan Said; Hooman Rashidi; Sheeja T Pullarkat
Journal:  Clin Rheumatol       Date:  2011-11-18       Impact factor: 2.980

Review 2.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

3.  Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.

Authors:  Sigurdur Y Kristinsson; Gloria Gridley; Robert N Hoover; David Check; Ola Landgren
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

4.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

5.  Risk of cancer among rheumatoid arthritis patients in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2009-01-28       Impact factor: 2.506

6.  Rheumatic diseases and malignancies.

Authors:  Violeta Bojinca; Iustina Janta
Journal:  Maedica (Buchar)       Date:  2012-12

7.  Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.

Authors:  W H Chow; G Gridley; L Mellemkjaer; J K McLaughlin; J H Olsen; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

8.  Felty's Syndrome, Insights and Updates.

Authors:  Mohammad Bagher Owlia; Kam Newman; Mojtaba Akhtari
Journal:  Open Rheumatol J       Date:  2014-12-31

Review 9.  Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Authors:  Sujani Yadlapati; Petros Efthimiou
Journal:  Biomed Res Int       Date:  2016-06-27       Impact factor: 3.411

10.  Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980-2007 in relation to a Comparator Cohort: A Population-Based Study.

Authors:  Shafay Raheel; Cynthia S Crowson; Kerry Wright; Eric L Matteson
Journal:  Int J Rheumatol       Date:  2016-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.